Moderna has given the first dose of the MRNA-based influenza vaccine to the participants in the initial phase clinical trial, the company announced Wednesday.

Moderna finally planned to test the vaccine in around 180 people in a random, multilevel, observer phase 1/2 trial. The trial will see security, different doses, and immune responses.

This vaccine, called MRNA-1010, is designed to target four lines of influenza virus circulating seasonally every year, just like the current quadrivalent flu vaccine on the market. The four virus lineages are identified by the World Health Organization as targeted for prevention of diseases every seasonal type of type h1n1 and H3N2 and H3N2 and type B Lineage Yamagata and Victoria influenza. If the MRNA-1010 proved to be effective against the annual outbreak in the next step trial, Modera aims to finally deliver it with three other MRNA-based vaccines to create an annual one-roof shot.

In addition to influenza, this imaginable combination shot will target two other respiratory viruses circulating with the Influenza-Respiratory (RSV) virus (RSV) and Human Metapneumovirus (HMPV) -Sagai Coronavirus, SARS-COV-2, which speculates some experts can be seasonal. At present, there are no licensed vaccines against RSV or HMPV. And it is not clear whether SARS-COV-2 will be seasonal and / or if the annual booster vaccine will be needed.

“We believe that the advantages of MRNA vaccines include the ability to combine different antigens to protect against many viruses and ability to quickly respond to the evolution of breathing viruses, such as influenza, SARS-COV-2 and RSV,” Stephane CEO “Bancel said in a statement. “Our vision is to develop a MRNA combination vaccine so that people can get one shot every fall for high efficacy protection against the most problematic respiratory virus.”